Post-IPO Equity - Kala Pharmaceuticals - 2021-11-29 - Crunchbase

Kala Pharmaceuticals raised $16122541 on 2021-11-29 in Post-IPO Equity. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log …

CouponFollow Extension

$16122541
OFF

Post-IPO Equity - Kala Pharmaceuticals - 2021-11-29 - Crunchbase

1 week from now

Kala Pharmaceuticals raised $16122541 on 2021-11-29 in Post-IPO Equity. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log …

crunchbase.com

$31
OFF

Kala Pharmaceuticals Reports Fourth Quarter And Full Year 2022 ...

1 week from now

Mar 3, 2023 · -- Enrolled first patient in CHASE Phase 2b clinical trial evaluating KPI-012 for PCED; Top-line data targeted for 1Q 2024 -- -- Closed $31.0 million private placement …

yahoo.com

$11
OFF

Kala Pharmaceuticals Reports Fourth Quarter And Full Year 2021 ...

1 week from now

Mar 29, 2022 · -- Achieved $11.2 Million in Net Revenue in 2021 ---- Expanded Coverage for EYSUVIS® to 118 Million Commercial Lives and 7.1 Million Medicare Lives ---- KPI-012 Phase …

yahoo.com

$150
OFF

Staying Patient With Kala Pharmaceuticals - Seeking Alpha

1 week from now

Aug 29, 2021 · As of June 30th, 2021, the company had approximately $150 million in cash and marketable securities on its balance sheet after posting a net loss of $29 million for the quarter …

seekingalpha.com

$115
OFF

Kala Pharmaceuticals - Raised $115M Funding From 16 Investors

1 week from now

Nov 5, 2024 · Kala Pharmaceuticals has raised a total funding of $115M over 11 rounds from 16 investors. Investors include Athyrium Capital Management, Vivo Capital and 14 others. ... Feb …

tracxn.com

$124
OFF

Kala Pharmaceuticals Reports Third Quarter 2021 Financial Results …

1 week from now

Cash Position: As of September 30, 2021, Kala had cash and cash equivalents of $124.5 million, compared to $149.6 million of cash, cash equivalents and short-term investments as of June …

kalarx.com

$31000000
OFF

Post-IPO Equity - Kala Pharmaceuticals - 2022-11-28 - Crunchbase

1 week from now

Kala Pharmaceuticals raised $31000000 on 2022-11-28 in Post-IPO Equity. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log …

crunchbase.com

$86
OFF

Kala Pharmaceuticals Files For $86 Million IPO - Seeking Alpha

1 week from now

Jun 27, 2017 · Kala Pharmaceuticals wants to raise up to $86.25 million in an IPO. ... routes is to reach $1.67 billion by 2021. ... but has not provided an expected share price range or …

seekingalpha.com

$125000000
OFF

Post-IPO Debt - Kala Pharmaceuticals - 2021-05-12 - Crunchbase

1 week from now

May 13, 2021 · Kala Pharmaceuticals raised $125000000 on 2021-05-12 in Post-IPO Debt. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. …

crunchbase.com

750%
OFF

KALA BIO, Inc. (KALA) Stock Price, Quote & News - Stock Analysis

1 week from now

4 days ago · Kala Pharmaceuticals stock up 750% in 3 days after upbeat FDA news on PCED treatment. Shares of Kala Pharmaceuticals Inc. KALA, +39.53% have rocketed higher in for …

stockanalysis.com

14%
OFF

Kala Pharmaceuticals (KALA) Reports Q4 Loss, Lags Revenue …

1 week from now

Mar 29, 2022 · Kala Pharma (KALA) delivered earnings and revenue surprises of -58.14% and 45.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to …

yahoo.com

$7.50
OFF

Kala Pharmaceuticals Stock Price - Markets Insider

1 week from now

Jun 25, 2024 · On Monday 11/11/2024 the closing price of the Kala Pharmaceuticals Inc Registered Shs share was $7.50 on BTT. Compared to the opening price on Monday …

businessinsider.com

$134000000
OFF

Post-IPO Equity - Kala Pharmaceuticals - 2020-04-06 - Crunchbase

1 week from now

Kala Pharmaceuticals raised $134000000 on 2020-04-06 in Post-IPO Equity. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. Resources. Log …

crunchbase.com

$12500000
OFF

Post-IPO Equity - Kala Pharmaceuticals - 2024-06-27 - Crunchbase

1 week from now

Jun 27, 2024 · Kala Pharmaceuticals raised $12500000 on 2024-06-27 in Post-IPO Equity. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. …

crunchbase.com

FAQs about Post-IPO Equity - Kala Pharmaceuticals - 2021-11-29 - Crunchbase Coupon?

What is Kala Pharmaceuticals Inc registered SS's market capitalization?

Kala Pharmaceuticals Inc Registered Shs's market capitalization is $21.18 M by 2.69 M shares outstanding. *The average price target includes all analyst analysis, not just the most recent analysis presented in the chart. Selling, General & Admin. Exp. * Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet ...

Did Kala give a new employee non-statutory stock options?

ARLINGTON, Mass., July 19, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement aw... ...

How much did Kala pharmaceuticals (Kala) lose?

Kala Pharmaceuticals (KALA) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -58.14%. ...

What was the closing price of Kala Pharmaceuticals Inc registered SHS?

On Friday 03/22/2024 the closing price of the Kala Pharmaceuticals Inc Registered Shs share was $7.88 on BTT. Compared to the opening price on Friday 03/22/2024 on BTT of $7.85, this is a gain of 0.38%. Kala Pharmaceuticals Inc Registered Shs's market capitalization is $21.18 M by 2.69 M shares outstanding. ...

Does Kala bio offer non-statutory stock options?

ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside ... ...

Will Kala's net revenues be negatively impacted in 2021?

Kala expects that net revenues could continue to be negatively impacted in 2021. Preclinical Development Program Pipeline: Kala is progressing a pipeline of preclinical development programs targeted to address front and back of the eye diseases. ...